Magnesium and cardiovascular complications of chronic kidney disease

Area of Science:

• Nephrology
• Cardiology
• Mineral Metabolism

Background:

• Cardiovascular complications are the primary cause of death in chronic kidney disease (CKD) patients.
• Magnesium is known to influence cardiovascular function and disease in the general population.
• The specific role of magnesium in CKD-related mineral and bone disorders and its impact on cardiovascular outcomes remains unclear.

Purpose of the Study:

• To investigate the role of magnesium in cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD).
• To evaluate the impact of magnesium on vascular calcification, cardiovascular events, and mortality in CKD.
• To highlight the need for robust clinical trials on magnesium supplementation in CKD.

Main Methods:

• Review of experimental studies demonstrating magnesium's inhibitory effects on vascular calcification.
• Analysis of epidemiological studies associating serum magnesium levels with cardiovascular outcomes in CKD patients.
• Assessment of existing intervention trials in CKD patients, noting their limitations in sample size and outcome measures.

Main Results:

• Experimental data suggest magnesium inhibits vascular calcification through direct and indirect mechanisms.
• Epidemiological studies show correlations between serum magnesium levels and adverse cardiovascular outcomes, including vascular calcification, events, and mortality in CKD.
• Previous intervention trials in CKD have primarily used surrogate parameters like arterial stiffness and atherosclerosis.

Conclusions:

• Magnesium's role in cardiovascular health within the CKD population requires further elucidation.
• Current evidence suggests a link between magnesium levels and cardiovascular risk in CKD.
• Well-designed randomized controlled trials are essential to determine the efficacy of magnesium supplementation on hard cardiovascular outcomes in CKD patients.